BRPI0920552A2 - nanosistemas poliméricos auto-organizáveis multifuncionais - Google Patents

nanosistemas poliméricos auto-organizáveis multifuncionais

Info

Publication number
BRPI0920552A2
BRPI0920552A2 BRPI0920552A BRPI0920552A BRPI0920552A2 BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2 BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A BRPI0920552 A BR PI0920552A BR PI0920552 A2 BRPI0920552 A2 BR PI0920552A2
Authority
BR
Brazil
Prior art keywords
organizing
multifunctional self
nanosystems
polymeric
polymeric nanosystems
Prior art date
Application number
BRPI0920552A
Other languages
English (en)
Inventor
K Iyer Arun
M Amiji Mansoor
Original Assignee
Univ Northeastern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northeastern filed Critical Univ Northeastern
Publication of BRPI0920552A2 publication Critical patent/BRPI0920552A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
BRPI0920552A 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais BRPI0920552A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10405608P 2008-10-09 2008-10-09
US24635509P 2009-09-28 2009-09-28
PCT/US2009/060175 WO2010042823A1 (en) 2008-10-09 2009-10-09 Multifunctional self-assembling polymeric nanosystems

Publications (1)

Publication Number Publication Date
BRPI0920552A2 true BRPI0920552A2 (pt) 2019-09-24

Family

ID=42100975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920552A BRPI0920552A2 (pt) 2008-10-09 2009-10-09 nanosistemas poliméricos auto-organizáveis multifuncionais

Country Status (7)

Country Link
US (1) US9173840B2 (pt)
EP (1) EP2352490A4 (pt)
JP (1) JP2012505243A (pt)
AU (1) AU2009302217A1 (pt)
BR (1) BRPI0920552A2 (pt)
CA (1) CA2740125A1 (pt)
WO (1) WO2010042823A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8333962B2 (en) * 2009-08-27 2012-12-18 National Health Research Institutes Controlled release multidrug formulations for spinal cord injury
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
US9918656B2 (en) * 2010-06-25 2018-03-20 Massachusetts Institute Of Technology Implantable magnetic relaxation sensors and methods of measuring a sensor's cumulative exposure to a biomarker
WO2012017307A1 (en) * 2010-08-05 2012-02-09 Council Of Scientific & Industrial Research A process for the removal of polymer thermosets from a substrate
CA2819240C (en) 2010-12-02 2021-06-15 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
US20140037748A1 (en) * 2011-04-15 2014-02-06 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES TARGETING APOPTOSIS
US9872870B2 (en) 2011-11-04 2018-01-23 University Of Notre Dame Du Lac Multifunctional micellar nanoparticle-based drug and targeting agent system
KR101722948B1 (ko) * 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
WO2013089522A1 (ko) * 2011-12-15 2013-06-20 (주)바이오니아 신규한 올리고뉴클레오티드 접합체 및 그 용도
ES2669561T3 (es) 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanopartículas para el transporte mitocondrial de agentes
US20130261444A1 (en) * 2012-03-28 2013-10-03 The Uab Research Foundation Photothermal nanostructures in tumor therapy
JP2015519312A (ja) * 2012-04-19 2015-07-09 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 高度分岐α−Ｄ−グルカン
WO2013163234A1 (en) * 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
WO2014008283A2 (en) * 2012-07-02 2014-01-09 Northeastern University Biodegradable polymeric buffers
WO2014110449A1 (en) * 2013-01-10 2014-07-17 Amrita Vishwa Vidyapeetham Stannous doped micro and nano particles for augmented radiofrequency ablation
US10342846B2 (en) 2013-02-04 2019-07-09 University Of Notre Dame Du Lac Nanoparticle drug delivery systems
WO2015002511A1 (ko) 2013-07-05 2015-01-08 (주)바이오니아 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법
WO2015002512A1 (ko) 2013-07-05 2015-01-08 (주)바이오니아 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
EP3258922A1 (en) * 2015-02-18 2017-12-27 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
JP6752231B2 (ja) 2015-06-01 2020-09-09 カリフォルニア インスティテュート オブ テクノロジー 抗原を用いて特異的集団に関してｔ細胞をスクリーニングするための組成物および方法
CN105878212B (zh) * 2016-05-27 2018-06-15 四川大学 一种双重细胞微环境敏感的抗肿瘤载药纳米胶囊及制备方法
CN106727423A (zh) * 2016-10-13 2017-05-31 中国药科大学 一种具有双靶向性的氧化还原敏感性的核交联普鲁兰多糖纳米粒及制备方法
CA3056802A1 (en) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Non-viral, non-cationic nanoparticles and uses thereof
WO2018170398A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
CN111918675A (zh) 2018-03-28 2020-11-10 格林马克生物医药股份有限公司 磷酸盐交联淀粉纳米颗粒和牙科治疗
CN108562564B (zh) * 2018-03-29 2021-04-02 青岛大学 一种用于菊糖酶活度检测的碳量子点及制备方法和应用
CN109021587B (zh) * 2018-06-07 2020-12-04 宁夏金博乐食品科技有限公司 可食用的明胶基膜及其制备方法
EP3921418A4 (en) * 2019-02-06 2023-02-08 Singular Genomics Systems, Inc. COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
JPS6319561A (ja) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺癌単クロ−ン性抗体
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
ATE162308T1 (de) 1987-07-15 1998-01-15 Us Health Monoklonale antikörper der zweiten generation mit bindungsspezifität für tag-72 und menschliche karzinome sowie methoden zu ihrer anwendung
US5543508A (en) 1987-12-15 1996-08-06 Gene Shears Pty. Limited Ribozymes
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (ja) 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6083696A (en) 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
DE69432926T2 (de) 1993-02-05 2004-05-13 Epigen, Inc., Wellesley Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6441158B1 (en) 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
US6458559B1 (en) 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
HUP0202177A3 (en) 1999-07-14 2004-05-28 Alza Corp Mountain View Neutral lipopolymer and liposomal compositions containing same
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
AU2006221448B2 (en) * 2005-03-09 2012-03-15 Toray Industries, Inc. Microparticle and pharmaceutical composition
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
MX2007012157A (es) * 2005-04-01 2008-03-14 Intezyne Technologies Llc Micelas polimericas para suministro de farmacos.
US20070048383A1 (en) 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) * 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties

Also Published As

Publication number Publication date
AU2009302217A1 (en) 2010-04-15
CA2740125A1 (en) 2010-04-15
EP2352490A4 (en) 2013-11-20
US20110244048A1 (en) 2011-10-06
WO2010042823A1 (en) 2010-04-15
US9173840B2 (en) 2015-11-03
JP2012505243A (ja) 2012-03-01
EP2352490A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
BRPI0920552A2 (pt) nanosistemas poliméricos auto-organizáveis multifuncionais
NO2021006I1 (no) Quofenix, delafloksacin
CR10926A (es) Nuevas 2-aminooxazolinas como ligandos taar1
DK2481796T3 (da) Glucoamylasevarianter
DE112009001577A5 (de) Verstellpumpe
BRPI0918087A2 (pt) construção de edifício
BRPI0911364A2 (pt) tienopirimidinas
BRPI0919559A2 (pt) baterias
FI20086252A0 (fi) Radiovastaanotin
BRPI0905074A2 (pt) Desidratador
DE102009055010A8 (de) Dachanordnung
FR2951218B1 (fr) Pylone de communication
FI20085902A0 (fi) Porrasrakenne
ES1070015Y (es) Rastrillo multifuncional
ES1068010Y (es) Unidad solar movil
ATE521549T1 (de) Verschlusskappe
UA20145S (uk) Ринва
ES1068560Y (es) Parapeto mejorado
ES1065566Y (es) Vallado multifuncional
ITPN20080016U1 (it) Chiosco mobile
ES1071223Y (es) Farola
TH116718B (th) เพสต์เพื่อการกันรั่ว
ES1067637Y (es) Separador balistico
ES1068033Y (es) Televisor multifuncional
ES1068050Y (es) Estructura de invernadero

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.